documents: FDA-2026-N-3273-0001
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | agency_id | docket_id | title | document_type | subtype | posted_date | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2026-N-3273-0001 | FDA | FDA-2026-N-3273 | Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments | Notice | Request for Comments | 2026-04-15 | 2026 | 4 | 2026-04-15 | 2026-07-24 | 2026-04-15 17:05:22 | 2026-07248 | 1 | 0 | 09000064b9282224 |